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ABSTRACT
PATRICK PIERCE BODDIE: Purification Protocol Development and Analysis of
Binding Properties of Calmodulin Collagen-Like Protein.
(Under the direction of Dr. Susan Pedigo)

Calmodulin is an intensely studied, intracellular, calcium-binding protein that is
involved in diverse physiological processes. When bound to calcium, calmodulin
undergoes a conformational change that allows it to bind specific target peptides with
high affinity, one being the calmodulin binding region of myosin light chain kinase,
herein called M13. This high affinity, calcium dependent association has made it a
desirable choice for use in a biomaterial for drug delivery for non-steroidal antiinflammatory drugs (NSAIDs). Two artificial genes have been designed by our lab for
use in the proposed biomaterial: calmodulin collagen-like protein (CCLP), a construct
composed of two calmodulin genes connected with a gene coding for three repeats of a
short collagen sequence; and PCLP, a construct composed of two repeats of M13
connected with same collagen repeats. Mixture of the two recombinant protein products
should form a gel in the high extracellular calcium concentration found in vivo. In order
to establish the viability of this novel biomaterial, we had to establish 1) protocols for
expression and purification of CCLP, and 2) whether or not the calmodulin regions of
CCLP retained their calcium-dependent binding of M13. In order to proceed with
experimentation, a consistent protocol for the production and purification of the CCLP
protein was developed. Confirmation of purity and concentration was obtained with SDSPAGE and UV-Visible spectroscopy, respectively. Second, because M13 undergoes a
change in secondary structure upon binding, CCLP’s interaction with M13 was
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monitored via circular dichroism spectroscopic studies. Results of these studies indicate
that we have an efficient expression and purification protocol for CCLP, and that CCLP
binds calcium and M13 according to its design.
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INTRODUCTION
1. APPLICATION

Inflammation is a beneficial process that the human body uses to remove
damaged tissues and destroy foreign intruders1. Inflammatory markers, or prostaglandins,
are paracrine hormones released by damaged tissues to recruit immune cells and increase
blood flow to the location of diseased tissue. Temporary pain, swelling, and local
acidification normally accompany this cascade of events, subsiding once the damage has
been repaired or cleared. Chronic inflammation, however, is an abnormal autoimmune
response where prostaglandin signaling is unwarranted and causes damage to healthy
body tissues, leading to disease2.
Chronic inflammation has been linked to the development of many serious
conditions such as diabetes3, cancers4, cardiovascular disease, and different
neurodegenerative disorders5. Because pain is a common symptom of chronic
inflammation, those suffering from the disorder often rely on nonsteroidal antiinflammatories (NSAIDs) for relief6. NSAIDs, also known as COX-1 or COX-2
inhibitors, are taken orally and circulate systemically to inhibit cyclooxygenase (COX),
the first enzyme in the pathway to the production of prostaglandins7. While COX
inhibitors are an effective treatment for chronic inflammation, the prostoglandins they
produce serve another important role in human physiology; they are vital to the
maintenance of the protective mucosal layer of the gastrointestinal (GI) tract8. Prolonged,
systemic delivery of COX inhibitors disrupts the GI tract’s ability to maintain its
protective mucosal layer and ultimately leads to ulcers and other gastrointestinal
ailments9, 10. The purpose of our work is to develop a bio-compatible material that will be
11

assembled and embedded in vivo at the site of chronic inflammation. The proposed
biomaterial will be covalently modified with NSAIDs through hydrolysable linkages to
allow in situ delivery of COX inhibitors at the site of inflammation. This is beneficial
because it will allow the drug to take effect locally in much lower doses, and will
dynamically respond to the acidification of tissues seen during the inflammatory
process11. These advantages will potentially allow long term use of NSAIDs with much
lower risk of the harmful side-effects.

2.

CALMODULIN AND M13

Calmodulin (CaM) is a ubiquitous, intracellular protein that regulates the activity
of many target enzymes. A few of its many regulatory roles include the contractile state
of smooth muscle12, short and long-term potentiation in neurons13, and lipid
metabolism14. CaM, a natural intracellular protein, was chosen as the basis for the
biomaterial for three primary reasons. First, high affinity for binding specific ligands
allows the development of two independent protomers, one with CaM and the other with
a peptide binding partner, M13, that will interact specifically to create the gel matrix.
Second, its calcium-dependent function will allow assembly of the biomaterial in the high
calcium concentrations in the extracellular (EC)- space. Third, its resilience towards its
chemical environment will allow chemical modification of the CaM-based component for
the purpose of covalent modification with drugs. In the remainder of this section,
calmodulin and M13, the CaM-binding component from myosin light chain kinase, will
be discussed in detail.
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Calcium Response
Calcium signalling occurs due to large intracellular transmembrane gradients that
exist between the endoplasmic reticulum and the cytosol, or between the EC-space and
the cytosol; extracellular concentrations [1mM]15 far exceed intracellular cytosolic
concentrations [0.0001mM]16. Within the cell, calcium acts as a secondary messenger for
signal transduction pathways that are triggered when intracellular calcium levels are
increased by the opening of voltage gated ion channels or by release from the
endoplasmic reticulum within the cell. CaM works as the intracellular calcium sensor,
controlling the activity of enzymes in response to stimuli.
Four calcium ions bind to CaM’s four binding sites, located between residues 2132 and 57-68 in the N-terminal domain, and between residues 94-105, and 130-141 in the
C-terminal domain17. The binding of four calcium ions to the N- and C-terminal EF-hand
sites causes conformational change that exposes hydrophobic surface areas in each
domain. This conformational change increases CaM’s binding affinity for its target
proteins18. CaM’s specific, high affinity, calcium dependent association with peptides
resulting from its normal intracellular targets makes it ideal for use in biomaterials in the
high calcium environment of the EC-space.

Ligand Binding to M13
CaM’s ability to bind many different targets is due to noncovalent interactions.
The interaction of CaM with myosin light chain kinase (MLCK) has been thoroughly
studied. During contraction in skeletal muscle, calcium-bound CaM activates MLCK via
its CaM binding site. This CaM binding site contains residues 577-602 of MLCK, a 26
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residue segment called M13. Once CaM interacts with M13, M13 undergoes a
conformational change from random coil to α-helix and CaM becomes more compacted
as it wraps around the now helical peptide19.
This change in secondary structure of both the peptide and CaM will be exploited
in monitoring the interaction between CCLP and M13. Figure 1 illustrates the binding of
Ca2+ to CaM, and subsequent association with one of its physiological binding partners.

FIGURE 1: The Structure and Function of Calmodulin.
[Left] (A) Ribbon drawing of calmodulin with calcium binding regions (yellow). Two
EF-hand sites are located at the N-domain (blue), and two at the C-domain (red). The
central helix is disordered at the intersection of the two domains (black). (B) When
bound to calcium, the hydrophobic surface areas (orange) are exposed. (C) Ribbon
drawing of calmodulin binding a physiological partner (green). (D) Cartoon drawing of
interaction between calmodulin and its binding partner, showing the hydrophobic
surface areas interact.
[Right] Alignment of Calcium Binding Sites: EF-hand sites contain 12 residues, 6 of
which directly chelate calcium (red): five (X, Y, Z, -X, and –Y) offer one carbonyl
oxygen to chelate calcium; one (-Z) is a bidentate chelator of calcium. Consensus
sequence highlights the conserved residues. There are only 2 tyrosines and 4 serines and
no cysteine or tryptophan residues in CaM.
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Resilience of Calmodulin to Denaturation
CaM has two globular domains connected by a long central helix. As such, it has
more accessible surface area than a spherical protein. It is soluble in high concentration
and renatures when heat denatured or chemically denatured20. The best example of its
resilience to permanent denaturation is the protocol for its purification from tissue12. The
resilience of CaM makes it easy to purify from complex mixtures and enhances its ability
to withstand modification by organic reactions.

3. CCLP and PCLP

CCLP and PCLP are the protein constructs we designed for use in the proposed
biomaterial. These two constructs, respectively, incorporate repeats of CaM and M13 into
complex protomers of our particular design (Figure 2). The concept is that mixing of
these protomers in the EC-space in vivo will create a vast, multi-protomer 3D matrix
upon exposure to the high calcium environment that is the EC-space.

Figure 2: Design Concept of the CCLP and PCLP Constructs.
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(Figure 2 continued) A HisTag is at the N-terminus to simplify the purification
process. Two CaM repeats are linked in an alternating sequence with a collagen linker
sequence (CLS). These CLS regions contain serine and tyrosine residues for
modification and collagenase cleavage sites. A cysteine (Cys) residue is at the Cterminus to allow disulfide linkages between protomers or to insert specers. [Bottom]
A layout of the PCLP construct. M13 regions will be bound by the CaM regions of the
CCLP construct. *Dimensions are not to scale.
CCLP Domains
The amino acid sequence of the CCLP construct is described in detail in Figure 3.
The HisTag sequence present at the N-terminus allows for purification via HisTag
chromatography. HisTag chromatography is a simple and reliable method used to purify
genetically engineered proteins. We expect the CaM sequences in CCLP perform the
same binding function as their isolated form. Making this protein from a synthetic gene,
purifying it and ensuring that the CaM sequences bind peptide are the goals of this
project.
The CLS regions are composed of three short collagen repeats separated by
glycine (G), tyrosine (Y), and serine (S) residues (GSGYG). Tyrosine and serine residues
in the CLS region and those in the CaM sequences are the targets of the drug attachment
process described briefly below. The CLS contains a collagenase cleavage site
(GPQG/IWGQ) that was chosen since it is substrate for collagenases secreted by
inflamed tissues21. The choice to include 3 repeats of the CLS sequence was made so that
the CaM sequences would be separated in the final gel to eliminate crowding between
interacting protomers. A single cysteine residue, located at the C-terminus, will allow the
formation of disulfide linkages to occur between identical protomers thereby doubling the
numbers of CaM or M13 interaction sites in a protomer from 2 to 4. Additionally, spacer
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molecules such as divinyl sulfone polyethylene glycol can be inserted between protomers
to further diversify the structural capabilities of the proposed biomaterial.

MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGSMADQLTEE
QIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQDM
INEVDADGNGTIDFPEFLTMMARKMKDTDSEEEIREAFRVFDKD
GNGYISAAELRHVMTNLGEKLTDEEVDEMIREADIDGDGQVNYE
EFVQMMTAKELQGPQGIWGQGSGYGGPQGIWGQGSGYGGPQ
GIWGQGRRSGYGGSMADQLTEEQIAEFKEAFSLFDKDGDGTITT
KELGTVMRSLGQNPTEAELQDMINEVDADGNGTIDFPEFLTMM
ARKMKDTDSEEEIREAFRVFDKDGNGYISAAELRHVMTNLGEKL
TDEEVDEMIREADIDGDGQVNYEEFVQMMTAKELQGPQGIWGQ
GSGYGGPQGIWGQGSGYGGPQGIWGQGSGYGRSC
Figure 3: CCLP Amino Acid Sequence.
The HisTag region (grey) is composed of His6 for HisTag chromatography. Each CaM
sequence (blue) provides calcium dependent binding activity to the construct.
Collagenase cleavage sites (green) are separated by the modification sequences
(underlined). The cysteine residue (red) will allow disulfide linkage to occur between
constructs in order to further diversify potential matrix structures.
Modification of CCLP with NSAIDs
The 23 serine (S) residues and 10 Tyrosine (Y) residues present in the CCLP
construct will be the targets for modification with NSAID drugs. There are also 17 amine
residues that have the potential to be modified during the process. These modifiable
residues are located on the surface of the CaM repeats and within the exposed
modification sequences of the CLS region. Figure 4 shows the structure of Aspirin and
Naproxen, the two NSAIDs that will be used to modify the constructs. Hydrolysis of ester
linkages is increased in acidic environments22.
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Figure 4: Aspirin and Naproxin.
[Left] The structure of Aspirin. [Right] The structure of Naproxin. Ester or amide linkage
to CCLP will be made at the hydroxyl group of each carboxylic acid.
Responsive Biomaterial
Because of their design, CCLP and PCLP will bind in a way that forms a vast,
random 3D matrix. Figure 5 illustrates just one of the many ways that the two constructs
may associate. Disulfide linked protomers will double the number of “nodal” sites from 2
to 4 for interacting protomers.

Figure 5: Illustration of “Gel” Matrix Formed by CCLP and PCLP Interaction.

18

(Figure 5 continued) This illustrates the association of CCLP with PCLP into a matrix
upon exposure to high EC Ca2+ in vivo. While the matrix depicted is uniform, many
possible patterns of association between the two constructs can exist.
Once placed in the inflamed region of the body, the inflammatory process will
speed the release of drug and the breakdown of the matrix. The low pH created by the
inflamed tissue will drive the hydrolysis of NSAID molecules from modified residues.
Collagenases will break down the matrix by cleaving the sites located within the CLS
region of the construct. When inflammation is lessened due to NSAID release, pH will
increase, and the gel will stabilize; cleavage of the ester linkages and the activity of the
collagenases will decrease.
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EXPERIMENTAL PROCEDURES

EXPERIMENT 1: Overexpression and Purification of CCLP in BL21(DE3) E. Coli.
The first goal of my research was to confirm that the CCLP construct can be
expressed in E. Coli and purified. Figure 6 shows a summary of the procedure that was
established. This section will describe the specifics of the components of this protocol.

Figure 6: Summary of Transformation, Overexpression and Purification Procedures.
This flowchart illustrates a summary of the developed protocol for the production and
recovery of purified CCLP.

Plasmid Design
Figure 7 shows the mechanism for the bacterial production of the CCLP protein
construct. A plasmid containing the designed CCLP gene was transformed into
BL21(DE3) E. Coli. The cell line contains the gene for T7 polymerase following a lac
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promoter that is inducible by IPTG. The CCLP gene is placed following a T7 promoter
region. Once transcribed and translated, T7 polymerase attaches to the T7 promoter
region of the plasmid and transcribes the CCLP gene. Expression cell lines containing the
plasmid are frozen in dilute glycerol solutions so that transformed cells are readily
accessible.

Figure 7: Detailed Mechanism of the CCLP Plasmid.
IPTG (red) derepresses the lac promoter (blue) present in the chromosomal DNA of
BL21(DE3) E. Coli. This causes the production of T7 Polymerase (green). T7
Polymerase then binds to the T7 promoter region (orange) of the plasmid and transcribes
the CCLP gene, producing CCLP mRNA (yellow). The Kan region (pink) contains a
gene that confers resistance to the antibiotic kanamycin, allowing for the selection of
successfully transformed cells.

LB Agar Plates
Day 1: LB Agar plates with and without 30µg/mL kanamycin and liquid media were
prepared. In two 250mL Erlenmeyer flasks, 100mL of water, 2g tryptone, 1g yeast
extract, 1g NaCl, and 1.5g agar were combined and autoclaved. Once cooled to ~600C,
21

100µL of kanamycin stock (30mg/mL) was added to one plate. Five plates were poured
from each flask. These plates are used to streak cells from the frozen stocks of
transformed expression cell lines.
LB Liquid Cultures
Day 1: One 50mL sterile LB culture was prepared in a 250mL Erlenmeyer flask. 50mL
water, 1g tryptone, 0.5g yeast extract, and 0.5g NaCl were combined and autoclaved.
Three 1L LB cultures were then prepared and autoclaved in 2.5L Fernbach flasks
comprising 1L water, 20g tryptone, 10g yeast extract, and 10g NaCl.
Preparation of Colony
Day 1: Pre-transformed cells from the deep freezer were streaked onto two sterile plates
(LB and LB+Kan) with inoculation loop. They were incubated overnight at 37˚C.
Preparation of Overnight Culture
Day 2: A volume of 50µL of Kan stock was added to one 50mL LB culture. One colony
from the LB+Kan plate was taken with an inoculating loop used to inoculate the 50mL
LB+Kan culture. The inoculated culture was placed in the incubator at 37˚C with shaking
at 200rpm overnight.
Overexpression of CCLP
Day 3: A volume of 20mL 20% Glucose, 50mL of 1M potassium phosphate, 5mL of
overnight culture and 1mL kanamycin stock was added to each of the three 1L LB
cultures. They were placed on the rotating incubator at 37˚C at 200rpm. Cell growth was
monitored

with

UV-Visible

spectrophotometer

(Cary

50

Bio

UV-Visible

Spectrophotometer) with absorbance set at 600nm and blanked against LB culture only.
Once at mid-log phase (0.6AU; this usually takes ~5 to 6hrs), a 1mL sample was placed

22

in a labelled eppie, centrifuged (Fisher Scientific Micro Centrifuge Model 235C),
supernatant was decanted and the pellet was placed on ice. This sample is the preinduction sample for SDS-PAGE analysis. Then, a 1mL volume of 0.4M IPTG stock was
added to each 1L culture to induce expression of T7 RNA Polymerase and CCLP. We
waited 2hrs to allow bacteria to produce the CCLP. After 2hrs, the post-induction sample
was taken for a gel and frozen. The 1L culture were transferred into 1L centrifuge bottles
and centrifuged (Sorvall 5B Centrifuge) at 3000rpm for 15min at 40C. Supernatant was
decanted, pellets combined by suspension in 10mL of 20mM HEPES, 100mM KCl pH
7.4 buffer and frozen overnight.
Sonication and Pelleting of Cell Debris
Day 4: Thawed cells were transferred to a 200mL stainless steel beaker, and placed on
ice. Sonication with a blunt tip (2mins, 5sec pulse, 50% power) lysed cells, and a postsonication sample was removed for gel analysis. Sonicated cells were transferred into
Oakridge tubes and centrifuged (Sorvall 5B Centrifuge) at 12,000rpm, 4˚C for 45mins.
Supernatant was transferred into 100mL graduated cylinder, and a sample was taken for a
gel. The pellet was saved until the process was completed.
Heat Treatment of Supernatant
Day 4: The supernatant was brought to a final concentration of 50mM calcium, placed
into a water bath at 800C for 10mins, and then placed on ice for 10mins. Cold supernatant
was transferred into Oakridge tubes and centrifuged at 12,000rpm, 40C for 20mins.
Samples of supe and pellet were placed in eppies for a gel.
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Dialysis into HisTag Binding Buffer and Preparation of Chromatography Column
Day 4: Supernatant was transferred into 8,000 MWCO dialysis tubing and dialyzed for
24hrs against 1L of binding buffer (see composition below) in preparation for HisTag
chromatography. Buffer was exchanged after 12hrs.
HisTag Chromatography
Day 5: HisTag chromatography utilizes Nickel (II) ion stationary phase (Thermo
Scientific HisPur Ni-NTA Resin) that binds to the lone pairs present in the histidine
residues at pH levels above the pKa for their side chain hydrogens (pKa= ~6).
Chromatography buffers were prepared as follows: 1L Binding Buffer (0.02M Tris/HCl,
0.50M NaCl, 0.005M Imidazole, pH 7.9), 1L Wash Buffer (0.02M Tris/HCl, 0.50M
NaCl, 0.040M Imidazole, pH 7.9), and 1L Elution Buffer (0.010M Tris/HCl, 0.250M
NaCl, 0.5M Imidazole, pH 7.9). The column was then equilibrated with binding buffer. A
10mL volume of dialyzed supernatant was loaded onto the column and flow through was
collected in 15mL conicals. Protein was purified by application of 20mL binding buffer,
20 mL wash buffer, and 30mL elution buffer. All eluent was collected in 5 mL fractions
and assayed by UV visible spectroscopy in 2mm path length quartz cuvette to assess
concentration and to determine if protein has eluted properly. Samples were collected
from fractions that contained protein for assaying by SDS-PAGE. If more dialyzed
supernatant remains, this chromotography process is repeated.
Dialysis and Lyophilization
Day 6-7: Fractions containing purified protein were combined and transferred into 3-5kD
dialysis tubing and dialyzed against 1L water for 4hrs, and repeating six times while
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exchanging the water. The dialysate was frozen in a 50mL conical using an
acetone/ethanol bath and lyophilized to recover solid product.
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EXPERIMENT 2: Analysis of Binding of CCLP with M13 via Circular Dichroism
Spectroscopy.
CD spectroscopy is used to see the optical activity of asymmetric compounds, and
allows one to view the secondary structure of proteins. Each secondary structure gives a
unique signal. When analyzed with CD, CaM emits a strong alpha helical signal with a
distinct double minima that is characteristic of proteins that are predominantly helical.
This double minima can also be viewed in the CCLP construct. While unbound to CaM,
M13 assumes a random coil secondary structure. Once bound, M13 undergoes a
conformational change and organizes into an alpha helical secondary structure. Hence,
this change in the secondary structure of M13 upon association with the CaM regions of
CCLP was observed with CD spectroscopy and provides evidence of their interaction.
The absorbance value of CD spectroscopy can be defined as the the difference
between the absorption of left–handed circularly polarized light (LCP) and right—handed
circularly polarized light (RCP). LCP and RCP are directed through a solution of the
protein in question, and excite electrons in a direction opposite of the photons, creating a
measurable magnetic moment. When interpreting a CD spectrum, rather than referencing
absorbance at a specific wavelength, secondary structure is determined by viewing the
absorbance trend over a range of wavelengths. Each general secondary structure exhibits
its own graphical shape. Figure 8 contains examples of these secondary structure
graphical shapes.
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Figure 8: Example Secondary
Structure CD Spectra.
Each of the major secondary
structures can be identified by their
signature
CD
spectra.
When
monitoring alpha helical responses,
the stronger the minima, the greater
the content of alpha helices present
in the protein subject. Since M13
assumes alpha helix shape when
bound, this was used to determine if
CCLP binds M13.
*Figure taken from
http://www.ap-lab.com/circular_dichroism.htm

CD Spectroscopic Study on CCLP
The CCLP solution recovered from HisTag chromotography was dialyzed against 1L
SEC buffer (10mM HEPES, 140mM NaCl). The concentration of the protein stock was
then adjusted to 50µM. Three solutions of 50µM CCLP stock were prepared: Apo CCLP
(CCLP stock with 1 mM EDTA); CCLP+Ca2+ (CCLP stock, 1mM Ca2+); and
CCLP+Ca2++M13 (CCLP stock, 1mM Ca2+, M13). A solution of M13 peptide was also
prepared. Each solution was analyzed with a CD Spectrophotometer (Aviv Instruments
Model 202SF) by taking spectra between 200 to 300 nm, 1 nm increments, 5sec
averaging time. Temperature was ~ 25°C. Recovered data was parsed into Microsoft
Excel to produce a graph.
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RESULTS
Experiment 1: Overexpression and Purification of CCLP in BL21 (DE3) E. Coli.
The progress of experiment 1 was tracked with SDS-PAGE to assess the success of each
of the expression and purification steps (Figure 9). This method was used to judge the
purity of the CCLP solutions through each of the successive procedures. The molecular
weight of CCLP is 46.2 kD. Migration can be influenced by the presence of Ca2+ in
solution, although migration of the CCLP construct was consistent with its calculated
MW.

FIGURE 9: SDS-PAGE Analysis of CCLP Purification Process.
Lane 1 in each gel are molecular weight ladders (Fisher EZ-run Protein Marker). The
CCLP construct is 46.2 kD. The thick band present near the third band of the ladder is the
CCLP construct. [A] (2A) Pre- and (3A) post-induction of 1L cultures with IPTG. [B]
(2B) Pellet and (3B) supernatant post sonication. [C] Supernatant (2C) pre and (3C) post
heat treatment at 800C with 1mM Ca2+. [D] (2D) Pure CCLP recovered from HisTag
chromatography.
Gel A of Figure 9 shows transformed BL21(DE3) E. Coli before (2A) and 2hrs
after induction with IPTG (3A). The CCLP band at 46.2kD became noticeably thicker,
indicating that large quantities of CCLP were made. It is interesting to note that there is
some of the “expressed” recombinant protein in the pre-induction sample (2A) indicating
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that there was some “leaky” expression from the T7-promoter prior to induction of
transcription. After centrifugation of the induced cells, the cell pellet was sonicated and
centrifuged again to separate the soluble material from the insoluble. The resulting pellet
(2B) and supernatant (3B) show that the bulk of CCLP has remained in the supernatant
indicating that CCLP is soluble in aqueous solutions as we expected. Gel C shows the
purity of this supernatant before (2C) and after (3C) heat treatment at 800C with 1mM
Ca2+. Addition of calcium and heat treatment causes the normally clear solution of the
post-sonication supernatant to turn milky as most of the proteins denature and precipitate.
Fortunately, CCLP stayed in solution while other impurities were denatured and
precipitated. Lane 3C is remarkably enriched in CCLP as the bacterial proteins
precipitate, but impurities still remain. Lane 2D of Gel D shows the solution of the
combined elution fractions that contained CCLP after HisTag chromatography was
performed. The gel indicates that the sample is free from other protein contaminants after
HisTag chromatography.
The results of SDS-PAGE analysis have shown that the expression and
purification procedure described previously successfully expressed and purified CCLP in
from BL21(DE3) E. Coli. Solution D of Figure 9 was then dialyzed into water and
lyophilized, producing the solid shown in Figure 10. This lyophilized product will be
used for future experimentation towards the modification of hydroxyl-containing residues
with NSAID molecules.
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UV spectra of CCLP in water indicate that the protein has a spectrum characteristic of a
folded protein that contains both tyrosine and tryptophan residues.

Figure 10: Solid CCLP Recovered via Lyophilization and UV Spectra of HisTag Eluent.
[Right] UV visible spectra of CCLP post HisTag. A quartz cuvette with a pathlength of
2mm was used. Absorbance indicates an approximate concentration of 47µM according
to the Beer-Lambert law. [Left] Solid CCLP recovered from lyophilization was sent to
the Watkins Laboratory for experimentation towards the modification of hydroxyl
residues with NSAID molecules.
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Experiment 2: Analysis of Binding of CCLP with M13 via Circular Dichroism
Spectroscopy.
Evidence provided by the CD spectra of CCLP under each condition, shown in
Figure 11, suggests that the CCLP construct has retained its binding capabilities.
Figure 11: CD Spectra of CCLP Under
Various Conditions.
CD spectra recorded between 200260nm on 50µM CCLP stock in SEC
buffer. Confirmation of calcium binding
in the CCLP construct can be seen in the
signal change between apo and 1mM
Ca2+ environments. EDTA was used to
chelate unwanted Ca2+ in the apo
sample. M13 alone gives random coil
signal, Addition of M13 to CCLP in
1mM Ca2+ increases the alpha helical
signal and causes a disappearance of the
random coil.

Apo CCLP solution shows a double minima that is consistent with a alpha helical
secondary structure, showing that the CCLP regions have retained the structure
characteristic of the CaM components of the construct. Upon the addition of 1mM Ca2+, a
change in signal can be seen, indicating that the CaM regions of CCLP successfully bind
calcium. M13 peptide alone is unstructured as witnessed by the absence of helical or
sheet structure in the solution with peptide alone. Upon the addition of Ca2+ and M13
peptide to CCLP, the double minima shows an intensified signal. This is consistent with
the fact that when bound to CaM, M13 assumes a helical shape. This intensification of
alpha helix signal provides evidence that the CaM regions of CCLP construct
successfully bind M13 peptide.
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DISCUSSION
The experiments reported here are on a novel, in-house designed protein that is
one of the two components for a biomaterial whose purpose is to deliver antiinflammatory medications at the site of inflammation. The experiments reported here had
two primary purposes. First, we had to evaluate and optimize a purification protocol for
the protein from the bacterial contaminants of the expression system. Second, we had to
ensure that the CaM component of the protein was still functional in its new context.
Each of these two experiments will be discussed in turn.
The expression and purification protocol of CCLP employed both standard and
non-standard methods. The expression system that was used was designed to prevent
leaky expression in order to avoid the synthesis of proteins that would be toxic to bacteria
prior to induction23. We observed a band at the same MW as our product in the preinduction sample. This band may be a protein at the same MW as our CCLP construct,
or it may be actual CCLP that resulted from very low level transcription from the T7
promoter. By comparison of the pre- and postinduction lanes, it was clear that the protein
was not toxic to the cells since they continued to grow for two hours post induction. Postexpression cells are known to contain soluble CCLP because the construct was present in
the supernatant fraction post-sonication. Further, heat treatment of the supernatant is
rarely employed in the purification of proteins because it causes proteins to precipitate,
and precipitating protein can nucleate the precipitation of otherwise soluble proteins24.
Due to CaM’s incredible resilience to denaturation especially in the presence of
calcium20, it is able to withstand the extreme temperatures while almost of the bacterial
proteins are permanently denatured and precipitate. While HisTag chromatography has
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been shown to work well with CCLP, an alternative chromatography method, phenyl
sepharose chromatography, is an option for purification25. This method relies on the
hydrophobic interaction of the CaM regions of CCLP with the stationary phase of the
column. Once lyophilized, proteins are usually difficult to re-dissolve into aqueous
solution. CCLP did so very easily, requiring no special efforts. In summary, the
expression of CCLP and subsequent purification was very straightforward since the
designed CCLP construct offers many of the same advantages that isolated CaM has.
In contrast, the current PCLP construct has low solubility in aqueous
environment. Since the M13 sequence is highly basic, and therefore hydrophilic, this
implies that the CLS regions are highly insoluble. However, even with these hydrophobic
CLS regions, the hydrophilicity of CaM dominates the CCLP construct, making it highly
soluble. Both CCLP and PCLP are soluble in DMSO, which is a commonly used
ingredient in topical medications with low cellular toxicity26. DMSO is known to affect
the structure of proteins, however27.
When CaM binds to M13, it induces a conformational change in M13 from
random coil to helix. The change in CD spectra signal that accompanies this was shown
by Blumenthal et al in 198528. The 220nm minima provides the most reliable data point
because interference develops further into the UV spectrum. In Blumenthal’s study, the
ellipticity of CaM+Ca2++M13 at 220nm was higher than the sum of M13 and CaM
signals alone. This was due to the binding of CaM to M13 and the change of secondary
structure that resulted. This same logic was followed when designing the CD study on
CCLP, and the same observation was made.
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Future experiments must be done towards covalently modifying the CCLP
construct by esterification with Naproxen and Aspirin. and then determining whether the
modified form retains its peptide binding capabilities. Solubility issues with the PCLP
construct will also be addressed by altering its gene design. The CCLP construct is a
promising candidate for the future development of this novel biomaterial.
In conclusion, results show that we have successfully expressed and purified the
CCLP construct in BL21(DE3) E. Coli and determined that the CaM regions of the CCLP
construct have retained their peptide and calcium binding capabilities. As a parting
comment for this body of work, we would like to report the first attempt to make a gel
material from the PCLP and CCLP components. Austin Carroll, the student studying the
PCLP portion of the project, and I mixed samples of CCLP and PCLP in DMSO. We
then added Ca2+, and concentrated the solution. The result was a clear, viscous gel
substance shown in Figure 12. Under the direction of Dr. Pedigo with the assistance and
guidance of her graduate students, we have turned the concept of this biomaterial into a
reality.
Figure 12: CCLP and PCLP
Gel Substance.
This is an image of the gel
substance formed upon the
combination of CCLP and
PCLP in DMSO with Ca2+. The
formation of the gel was rapid
(<1min).

34

BIBLIOGRAPHY

1.

R., M. (2008) Origin and physiological roles of inflammation, Nature 454, 428.

2.

Grosser, T., Theken, K. N., and FitzGerald, G. A. (2017) Cyclooxygenase Inhibition:
Pain, Inflammation, and the Cardiovascular System, Clin. Pharmacol. Ther. 102, 611622.

3.

Haffner, S. M. (2006) The metabolic syndrome: inflammation, diabetes mellitus, and
cardiovascular disease, The American journal of cardiology 97, 3A-11A.

4.

van Kempen, L. C., de Visser, K. E., and Coussens, L. M. (2006) Inflammation, proteases
and cancer, European journal of cancer 42, 728-734.

5.

Ricciotti, E., and FitzGerald, G. A. (2011) Prostaglandins and inflammation,
Arteriosclerosis, thrombosis, and vascular biology 31, 986-1000.

6.

Statistics, N. C. f. H. (2014) National Ambulatory Medical Care Survey, National Center
for Health Statistics, Center for Disease Control: NAMCS/NHAMCS.

7.

Rao, P., and Knaus, E. E. (2008) Evolution of nonsteroidal anti-inflammatory drugs
(NSAIDs): cyclooxygenase (COX) inhibition and beyond, Journal of pharmacy &
pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical
Sciences, Societe canadienne des sciences pharmaceutiques 11, 81s-110s.

8.

Wallace, J. L. (2008) Prostaglandins, NSAIDs, and gastric mucosal protection: why
doesn't the stomach digest itself?, Physiol Rev 88, 1547-1565.

9.

Bjorkman, D. (1998) Nonsteroidal anti-inflammatory drug-associated toxicity of the
liver, lower gastrointestinal tract, and esophagus, The American journal of medicine 105,
17S-21S.

35

10.

Sostres, C., Gargallo, C. J., Arroyo, M. T., and Lanas, A. (2010) Adverse effects of nonsteroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal
tract, Best practice & research. Clinical gastroenterology 24, 121-132.

11.

Menkin, V., and Warner, C. R. (1937) Studies on Inflammation: XIII. Carbohydrate
Metabolism, Local Acidosis, and the Cytological Picture in Inflammation, The American
journal of pathology 13, 25-44 21.

12.

Walsh, M., and Stevens, F. C. (1977) Characterization of tryptic fragments obtained from
bovine brain protein modulator of cyclic nucleotide phosphodiesterase, J Biol Chem 252,
7440-7443.

13.

Lledo, P. M., Hjelmstad, G. O., Mukherji, S., Soderling, T. R., Malenka, R. C., and
Nicoll, R. A. (1995) Calcium/calmodulin-dependent kinase II and long-term potentiation
enhance synaptic transmission by the same mechanism, PNAS 92, 11175-11179.

14.

Nishizawa, Y., Okui, Y., and Inaba, M. (1988) Calcium/calmodulin-mediated action of
calcitonin on lipid metabolism in rats, Journal of Clinical Investigation 82, 1165-1172.

15.

Nicholson, C. (1980) Modulation of extracellular calcium and its functional implications,
Fed Proc 39, 1519-1523.

16.

Maravall, M., Mainen, Z. F., Sabatini, B. L., and Svoboda, K. (2000) Estimating
intracellular calcium concentrations and buffering without wavelength ratioing,
Biophysical journal 78, 2655-2667.

17.

Babu, Y. S., Bugg, C. E., and Cook, W. J. (1988) Structure of calmodulin refined at 2.2 A
resolution, J Mol Biol 204, 191-204.

18.

Rhoads, A. R., and Friedberg, F. (1997) Sequence motifs for calmodulin recognition,
FASEB J 11, 331-340.

19.

Hong, F., Haldeman, B. D., John, O. A., Brewer, P. D., Wu, Y. Y., Ni, S., Wilson, D. P.,
Walsh, M. P., Baker, J. E., and Cremo, C. R. (2009) Characterization of tightly associated

36

smooth muscle myosin-myosin light-chain kinase-calmodulin complexes, J Mol Biol 390,
879-892.
20.

Tsalkova, T. N., and Privalov, P. L. (1985) Thermodynamic study of domain
organization in troponin C and calmodulin, J Mol Biol 181, 533-544.

21.

Parks, W. C., Wilson, C. L., and Lopez-Boado, Y. S. (2004) Matrix metalloproteinases as
modulators of inflammation and innate immunity, Nature reviews. Immunology 4, 617629.

22.

Fersht, A. R., and Kirby, A. J. (1967) The hydrolysis of aspirin. Intramolecular general
base catalysis of ester hydrolysis, Journal of the American Chemical Society 89, 48574863.

23.

Studier, F. W., Rosenberg, A. H., Dunn, J. J., and Dubendorff, J. W. (1990) Use of T7
RNA polymerase to direct expression of cloned genes, Methods in enzymology 185, 6089.

24.

Gray, J. J. (2004) The interaction of proteins with solid surfaces, Current Opinion in
Structural Biology 14, 110-115.

25.

Shea, M. A., Verhoeven, A. S., and Pedigo, S. (1996) Calcium-induced interactions of
calmodulin domains revealed by quantitative thrombin footprinting of Arg37 and
Arg106, Biochemistry 35, 2943-2957.

26.

Santos, N. C., Figueira-Coelho, J., Martins-Silva, J., and Saldanha, C. (2003)
Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and
molecular aspects, Biochemical pharmacology 65, 1035-1041.

27.

Jackson, M., and Mantsch, H. H. (1991) Beware of proteins in DMSO, Biochimica et
biophysica acta 1078, 231-235.

28.

Blumenthal, D. K., Takio, K., Edelman, A. M., Charbonneau, H., Titani, K., Walsh, K.
A., and Krebs, E. G. (1985) Identification of the calmodulin-binding domain of skeletal

37

muscle myosin light chain kinase, Proceedings of the National Academy of Sciences of
the United States of America 82, 3187-3191.

38

